Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.
Latest Ratings for NVS
DateFirmActionFromTo Dec 2021Exane BNP ParibasDowngradesOutperformNeutral Dec 2021Bryan GarnierDowngradesBuyNeutral Sep 2021Deutsche BankDowngradesHoldSell